Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years, taking a down round and being disciplined
05 Mar 2024
AcquisitionIPOPhase 3Executive Change
Ken Song almost never got into radiopharmaceuticals. But after back-to-back phone calls from venture capital leaders at Versant and venBio in March 2020, the repeat life sciences CEO took a deep dive into the field, which at that point was outside the radar of most people in drug development.
Those calls worked, and Song would go on to lead RayzeBio, a Phase III oncology company bought by Bristol Myers Squibb in December for
$4.1 billion
. Blink too quickly, and pieces of the RayzeBio story could easily be missed. The company went from
Series A
to
Series B
in three months. Over 90 days, the 120-employee operation also went from
IPO
to acquisition.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.